Metabolic & weight

Retatrutide

An investigational triple agonist at the GIP, GLP-1 and glucagon receptors.

About

Retatrutide is an investigational peptide acting at three receptors. It has not been approved by any regulatory authority in any jurisdiction and remains in clinical development. No clean PubChem record exists for this compound; its identity is resolved here by CAS registry number. It is handled by individual professional consultation only, and its investigational status should be understood before any discussion.

Mechanism

The molecule is described as an agonist at the GIP, GLP-1 and glucagon receptors. The addition of glucagon receptor agonism is the distinguishing feature relative to dual agonists: glucagon signalling is associated with energy expenditure and hepatic lipid handling, pathways not engaged by incretin agonism alone. Because the compound is investigational, the mechanistic and safety picture is still being established.

What research has examined

Retatrutide has been evaluated in phase 2 clinical trials. Phase 3 programmes are ongoing and no regulatory approval exists.